GlassScriptPhysician profile
Linda Matonis
NPI 1851354534
$3,275.42
in general payments reported to CMS, 2019-2025
23 companies · $532 in 2025
The $532 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $408 · 2022: $777 · 2023: $940 · 2024: $619 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,090.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $509.28 | 2023-2025 | Veozah, Myrbetriq |
| Agile Therapeutics, INC. | $356.91 | 2021-2024 | Twirla |
| Therapeuticsmd, INC. | $249.94 | 2021-2022 | |
| Coopersurgical, INC. | $217.51 | 2021-2025 | Paragard T 380a, Paragard T 380a, Sos |
| Abbvie INC. | $217.41 | 2022-2024 | |
| Exeltis, USA INC. | $212.25 | 2021-2025 | Slynd |
| Exact Sciences Corporation | $189.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $188.32 | 2023-2025 | Myfembree, Gemtesa |
| Mayne Pharma Commercial LLC | $179.98 | 2021-2024 | |
| Pfizer INC. | $148.15 | 2022-2025 | |
| Millicent US INC | $138.41 | 2025 | Femlyv, Femring, Intrarosa |
| Merck Sharp & Dohme LLC | $128.71 | 2021-2024 | Gardasil 9, Gardasil |
| Myovant Sciences INC. | $125.81 | 2021-2022 | |
| Urovant Sciences INC | $70.56 | 2022 | |
| Organon LLC | $67.87 | 2022-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $59.68 | 2022-2023 | Prolia, Evenity |
| Mylan Pharmaceuticals INC. | $56.91 | 2021 | |
| Daiichi Sankyo INC. | $45.50 | 2023 | Injectafer |
| Sage Therapeutics, LLC | $45.48 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $19.52 | 2023 | |
| Scynexis, INC. | $17.53 | 2022 | |
| Abbott Laboratories | $15.50 | 2023 | Freestyle Libre 3 |
| Evofem Biosciences, INC. | $14.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Matonis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.